Synthetic GLP-1 receptor agonists, like semaglutide or liraglutide, have been shown to effectively lower blood sugar and aid in weight loss
According to Sehar Shahid, a pharmacy owner in Scotland, oral formulations will be easier to store and transport than current injectable pens, increasing access for patients
Summary: Mounjaro and Wegovy are both weekly GLP-1 receptor agonist injections for weight loss, but they vary in their actions, with Mounjaro being a dual receptor agonist, and Wegovy also approved for reducing cardiovascular risk
The rationale is that two smaller doses produce a more even medication level throughout the week, avoiding the peak-and-trough pattern that creates intense digestive effects early in the week and diminishing effects late in the week
In a study in which juvenile dogs received lisdexamfetamine dimesylate for 6 months beginning at 10 weeks of age, decreased bodyweight gain was seen at all doses tested (2, 5, and 12 mg/kg/day, which are approximately 0.5, 1, and 3 times the maximum recommended human daily dose on a mg/m2 basis for a child)
